zepbound and tirzepatide The FDA says the shortage is over. That's rattling the weight loss industry FDA approval for Zepbound (tirzepatide)

sitagliptin Sitagliptin Trade Name: Januvia Drug Class: oral hypoglycemics Mechanism of Action: An inhibitor of dipeptidyl peptidase-4 (DPP-4), a protease that degrades the incretin GLP-1 Incretins are hormones released from the GI tract in response to nutrient ingestion Incretins potentiate glucose-stimulated insulin secretion from beta cells in the pancreas As a result of inhibiting DPP-4, increased or prolonged GLP-1 levels are able to potentiate the secretion of insulin by the pancreas The effect produced by DPP-4 inhibitors is dependent on endogenous GLP-1 levels, and produce a modest effect on GLP-1 activity compared to giving GLP-1 receptor agonists (hence DPP-4 inhibitors do not have the same impact to produce weight loss as GLP-1 agonists)

So if you had to do your kind of top three, your superstars of nutrients for the brain and body

The Slinic Online Consultation serves as a vital diagnostic tool, allowing our specialist team to identify potential drug-drug interactions before they manifest clinically

Maturitas , 59(2), 149-157

But it also raises the risk of over-treatment, irritation, or adverse reactions if the timing is wrong